--- title: "Galectin Therapeutics (GALT) stock and investor profile" url: "https://aibio.space/companies/galectin-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Galectin Therapeutics Inc. (NASDAQ: GALT), United States. The directory classifies it as Biotechnology." --- GALT Galectin Therapeutics Inc. NASDAQ · United States # Galectin Therapeutics (GALT) news Debt Financing · 2025-07-09 ## [Galectin Therapeutics gets new $10 million credit line from chairman Richard Uihlein](https://aibio.space/news/galectin-therapeutics-gets-new-10-million-credit-line-chairman-richard/) The new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance. ## Latest Galectin Therapeutics news We have not published a story on Galectin Therapeutics yet. When there is news, it will appear here. ## Galectin Therapeutics at a glance - **Ticker**: GALT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $13.3 million ### Related companies - [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) NASDAQ: VIR - [XBiotech](https://aibio.space/companies/xbiotech/) NASDAQ: XBIT - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) NASDAQ: MCRB - [Heron Therapeutics](https://aibio.space/companies/heron-therapeutics/) NASDAQ: HRTX - [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) NASDAQ: CUE - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP ### Also on NASDAQ - [Tilray Brands](https://aibio.space/companies/tilray-brands/) TLRY - [PMGC Holdings](https://aibio.space/companies/pmgc/) ELAB - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) INDP - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [COOPER COMPANIES, INC.](https://aibio.space/companies/cooper-companies/) COO ## What Galectin Therapeutics does Galectin Therapeutics is a clinical stage biopharmaceutical company developing therapies for fibrotic disease, cancer and selected other diseases. Its drug candidates are carbohydrate-based compounds that bind and inhibit galectin proteins, particularly galectin-3. Its lead galectin-3 inhibitor, belapectin (GR-MD-02), is being studied for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis. The NAVIGATE trial, a Phase 2b/3 study of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis, randomized 357 patients by February 2023. In December 2024 the company reported top-line results: in the intent-to-treat population (N=355), the incidence of varices was reduced by 43.2% in the belapectin 2 mg/kg group versus placebo, but the composite endpoint did not reach statistical significance. In the per-protocol population (n=287), the incidence of varices was reduced by 49.3%. The company has also filed a new IND with the FDA for belapectin in combination with a PD-1 inhibitor for advanced or metastatic head and neck cancer, and says the proposed Phase 2 trial depends on the timing of financing. Galectin also operates Galectin Sciences LLC, a majority-owned joint venture developing small molecule galectin-3 inhibitors. | Product or program | What it is | Stage | |---|---|---| | Belapectin (GR-MD-02) | Galectin-3 inhibitor studied for esophageal varices prevention in MASH cirrhosis | Phase 2b/3 NAVIGATE trial; top-line results reported December 2024 | | Belapectin in head and neck cancer | Belapectin combined with a checkpoint (PD-1) inhibitor for advanced or metastatic head and neck cancer | Study May Proceed letter received; proposed Phase 2 depends on financing | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/ef20060823_10k.htm). ## Galectin Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$14.3 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | [$36.6 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | | Net income (loss) | [-$30.8 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | [-$47.0 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | | Cash from operations | [-$23.9 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | [-$41.8 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | | Cash and equivalents | [$17.7 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126032945/) | [$15.1 million](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Galectin Therapeutics What is the ticker symbol of Galectin Therapeutics? Galectin Therapeutics Inc. trades under the ticker GALT on NASDAQ. Where is Galectin Therapeutics listed? Galectin Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PHPN. What is the SEC CIK of Galectin Therapeutics? The SEC Central Index Key (CIK) for Galectin Therapeutics Inc. is 1133416. Its filings are on SEC EDGAR. How many shares does Galectin Therapeutics have outstanding? 100,849,644 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Galectin Therapeutics listed under? Our directory records Galectin Therapeutics Inc. under United States. What does Galectin Therapeutics do? Our directory classifies Galectin Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Galectin Therapeutics? The ISIN recorded for Galectin Therapeutics Inc. is US3632252025. Does aibio.space cover Galectin Therapeutics? aibio.space lists Galectin Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Galectin Therapeutics incorporated? SEC records list its state or country of incorporation as NV. What does Galectin Therapeutics develop? Galectin Therapeutics is a clinical stage biopharmaceutical company developing therapies for fibrotic disease, cancer and selected other diseases. Its drug candidates are carbohydrate-based compounds that bind and inhibit galectin proteins, particularly galectin-3. What is Belapectin (GR-MD-02) from Galectin Therapeutics? Belapectin (GR-MD-02): Galectin-3 inhibitor studied for esophageal varices prevention in MASH cirrhosis Stage: Phase 2b/3 NAVIGATE trial; top-line results reported December 2024. What is Belapectin in head and neck cancer from Galectin Therapeutics? Belapectin in head and neck cancer: Belapectin combined with a checkpoint (PD-1) inhibitor for advanced or metastatic head and neck cancer Stage: Study May Proceed letter received; proposed Phase 2 depends on financing. Is Galectin Therapeutics profitable? Galectin Therapeutics Inc. reported a net loss of $30.8 million for the fiscal year ended Dec 31, 2025, and used $23.9 million of cash in operations, per its annual report to the SEC. How much does Galectin Therapeutics spend on research and development? $14.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Galectin Therapeutics have? $13.3 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Galectin Therapeutics Members talk about Galectin Therapeutics (GALT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Galectin Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-04 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_ex99-1.htm) 2. 2026-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012155/ef20060823_10k.htm) 3. 2026-03-31 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012329/ny20068655x1_s3.htm) 4. 2025-12-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/ef20061484_ex99-1.htm) 5. 2025-07-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036125025295/ef20051584_ex99-1.htm) 6. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1133416/000114036125011169/ef20039001_10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GALT on TradingView](https://www.tradingview.com/symbols/NASDAQ-GALT/). ## SEC filings and registration - **SEC name**: Galectin Therapeutics Inc - **CIK**: 1133416 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GALT (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, 30071 - **Phone**: 678-620-3186 - **Shares outstanding**: 100,849,644 as of 2026-08-06 (10-Q filed 2026-08-14) - **Former names**: PRO PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1133416/000114036126039379/ny20080978x2_def14a.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_8k.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1133416/000114036126032945/ef20075252_10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_8-k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1133416/000114036126026031/ef20076593_8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_8k.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1133416/000114036126021495/ef20070490_10q.htm) filed 2026-05-15 - [S-3](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012329/ny20068655x1_s3.htm) filed 2026-03-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001133416), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Galectin Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GALT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Galectin Therapeutics Inc. - **Ticker**: GALT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US3632252025 - **Other listed symbols**: GETTEX:PHPN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GALT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/galectin-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Galectin Therapeutics (GALT) stock and investor profile", 2026-10-31, https://aibio.space/companies/galectin-therapeutics/